weekly_roundup
BioTechSign Daily Catalyst Roundup - November 07, 2026
Top BioTechSign catalyst names today: KURA, EYPT, SMMT, GRFS, NKTR, ARGX. FDA, clinical trial, grade-change, dilution, and sentiment signals.
BiotechSign AnalysisNovember 7, 2026
Daily Biotech Catalyst Digest: November 07, 2026
KURA leads the current BioTechSign screen at 86.6/100 with a grade of A. The daily view combines FDA timing, clinical activity, publications, dilution risk, short interest, institutional/fund flow, and market-sentiment convergence into one research queue.
Top Catalyst Scores
| Ticker | Company | Score | Grade | Strongest Inputs |
|---|---|---|---|---|
| KURA | Kura Oncology, Inc. | 86.6 | A | publication signal 100%, clinical activity 100%, short interest 70% |
| EYPT | EyePoint, Inc. | 84.8 | A | clinical activity 100%, short interest 70%, dilution risk 43% |
| SMMT | Summit Therapeutics Inc. | 75.4 | B | PDUFA timing 100%, publication signal 100%, clinical activity 100% |
| GRFS | Grifols SA | 74.8 | B | publication signal 100%, clinical activity 100%, dilution risk 19% |
| NKTR | Nektar Therapeutics | 74.0 | B | short interest 90%, clinical activity 75%, dilution risk 65% |
| ARGX | argenx SE | 74.0 | B | publication signal 100%, clinical activity 100%, dilution risk 15% |
Recent Grade-Change Queue
- KURA (Kura Oncology, Inc.) currently grades A with a 86.6/100 catalyst score. Main inputs: publication signal 100%, clinical activity 100%, short interest 70%.
- ACLX (Arcellx Inc) currently grades D with a 49.3/100 catalyst score. Main inputs: publication signal 100%, short interest 70%, clinical activity 46%.
- NVS (Novartis AG) currently grades F with a 20.9/100 catalyst score. Main inputs: clinical activity 25%, dilution risk 12%, short interest 10%.
- BGNE (BeiGene Ltd) currently grades F with a 14.2/100 catalyst score. Main inputs: publication signal 100%, clinical activity 12%.
- ABBV (AbbVie Inc) currently grades F with a 21.5/100 catalyst score. Main inputs: publication signal 100%, clinical activity 25%, dilution risk 10%.
- PYXS (Pyxis Oncology, Inc.) currently grades F with a 26.8/100 catalyst score. Main inputs: dilution risk 74%, short interest 50%, clinical activity 25%.
- NRIX (Nurix Therapeutics) currently grades D with a 36.0/100 catalyst score. Main inputs: publication signal 100%, short interest 70%, clinical activity 54%.
- ANVS (Annovis Bio, Inc.) currently grades D with a 39.8/100 catalyst score. Main inputs: clinical activity 62%, short interest 50%, insider buying 0%.
What To Watch
Names with high clinical-trial and publication inputs deserve a pipeline read-through. Names with elevated dilution or short-interest inputs deserve tighter risk review before any catalyst trade. The purpose of this feed is to surface candidates for research, not to make buy or sell recommendations.